Live Breaking News & Updates on South Eastern Norway Regional Health Authorities

Stay updated with breaking news from South eastern norway regional health authorities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immune-Mediated Inflammatory Diseases: Proactive Drug Monitoring Key to Improved Disease Control with Infliximab

Immune-Mediated Inflammatory Diseases: Proactive Drug Monitoring Key to Improved Disease Control with Infliximab
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.

United States , Principia Sanofi , Zenas Biopharma , Viela Bio , Silje Watterdal Syversen , Bristol Mysers Squibb , Liz Meszaros , Zacharys Wallace , Norwegian Regional Health Authorities , Bristolmyers Squibb , Harvard Medical School , Thermo Fisher , Rheumatology Research Foundation , South Eastern Norway Regional Health Authorities , Diakonhjemmet Hospital , Massachusetts General Hospital , Deputy Managing Editor , South Eastern Norway Regional Health , National Institutes , National Institute , Skin Diseases ,

Mixed Results with Refined Treatment Strategies for Rheumatic Diseases

May 5, 2021
Therapeutic drug monitoring, half-dosing may not be ready for prime-time
Therapeutic drug monitoring (TDM) for patients with immune-mediated inflammatory diseases did not lead to better clinical remission rates, while routine dose reduction of anti-rheumatic drugs for patients with rheumatoid arthritis (RA) in remission offered modest benefits, according to two Norwegian trials.
In the NOR-DRUM Part A trial, clinical remission at week 30 was achieved in 50.5% of 198 patients with TDM versus 53% of 200 patients in the standard therapy group, for an adjusted difference of 1.5% (95% CI −8.2% to 11.1%,
P=0.78), reported Silje Watterdal Syversen, MD, PhD, of Diakonhjemmet Hospital in Oslo, and co-authors.
In the ARCTIC REWIND trial, disease flare occurred in 25% of 77 patients in the half-dose conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) group versus 6% in the stable-dose csDMARD group for a risk difference of 18% (95% CI 7% ....

Silje Watterdal Syversen , Novartis Norge , Daiichi Sankyo , Eli Lilly , Infliximab Remicade , Siri Lillegraven , Shalmali Pal , Orion Pharma , Jeffreyr Curtis , Norwegian Regional Health Authorities , Boehringer Ingelheim , Thermo Fisher , University Of Alabama At Birmingham , South Eastern Norway Regional Health Authority , South Eastern Norway Regional Health Authorities , Research Council Of Norway , Diakonhjemmet Hospital , Contributing Writer , Norwegian Regional Health , Galderma Nordic , Bristol Myers Squibb , Merck Sharp , Research Council , South Eastern Norway Regional Health , Eisai Galapagos , தய்ச்சி சாங்கியோ ,